TD Asset Management Inc Raises Holdings in Prime Medicine, Inc. $PRME

TD Asset Management Inc raised its position in Prime Medicine, Inc. (NYSE:PRME) by 690.3% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 181,048 shares of the company’s stock after purchasing an additional 158,138 shares during the period. TD Asset Management Inc owned 0.13% of Prime Medicine worth $1,003,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in PRME. AQR Capital Management LLC boosted its stake in Prime Medicine by 1,419.4% during the first quarter. AQR Capital Management LLC now owns 243,795 shares of the company’s stock worth $485,000 after buying an additional 227,749 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in Prime Medicine in the first quarter valued at $101,000. Rhumbline Advisers grew its holdings in shares of Prime Medicine by 13.8% during the 1st quarter. Rhumbline Advisers now owns 81,900 shares of the company’s stock worth $163,000 after purchasing an additional 9,944 shares during the period. Savant Capital LLC purchased a new stake in Prime Medicine in the 2nd quarter valued at about $37,000. Finally, Creative Planning acquired a new stake in shares of Prime Medicine during the second quarter valued at about $25,000. 70.37% of the stock is currently owned by institutional investors and hedge funds.

More Prime Medicine News

Here are the key news stories impacting Prime Medicine this week:

• Positive Sentiment: Lifesci Capital reiterated an “Outperform” rating with a $6.00 price target and modeled FY2026 EPS of ($0.90), notably less negative than the current consensus of ($1.68), suggesting expected improvement in the company’s loss profile. Lifesci Capital estimates and rating
• Positive Sentiment: An analyst-consensus summary showed Prime Medicine has an average analyst rating of “Moderate Buy,” which can attract buying interest from funds and retail investors. Prime Medicine receives average “Moderate Buy”
• Neutral Sentiment: Lifesci published granular quarterly EPS forecasts (Q4 2025 and each quarter of 2026 at ~$ (0.23) per quarter) that give investors a clearer guidance baseline for modeling cash needs and runway but don’t change near-term operations. Detailed quarterly EPS estimates
• Negative Sentiment: Despite the upbeat ratings, forecasts still show the company remaining unprofitable next year (negative EPS), underscoring execution and funding risk for a clinical-stage biotech; this keeps downside risk if pipeline progress or financing plans disappoint. Consensus earnings context

Prime Medicine Stock Down 4.6%

Shares of Prime Medicine stock opened at $3.93 on Friday. The firm has a market capitalization of $709.41 million, a P/E ratio of -1.92 and a beta of 2.56. Prime Medicine, Inc. has a 52 week low of $1.11 and a 52 week high of $6.94. The firm’s 50 day moving average is $3.82 and its two-hundred day moving average is $4.17.

Analysts Set New Price Targets

A number of brokerages have issued reports on PRME. Chardan Capital cut their target price on Prime Medicine from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday, November 10th. Citigroup lowered their price objective on shares of Prime Medicine from $5.00 to $4.25 and set a “neutral” rating for the company in a research note on Tuesday, November 11th. Lifesci Capital began coverage on shares of Prime Medicine in a research note on Tuesday, December 23rd. They issued an “outperform” rating and a $6.00 price target for the company. Finally, Wedbush reaffirmed an “outperform” rating and issued a $8.00 price target on shares of Prime Medicine in a research report on Monday, November 10th. Four equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.21.

About Prime Medicine

Prime Medicine, Inc (NYSE: PRME) is a clinical-stage genetic medicines company focused on harnessing the potential of prime editing, an advanced CRISPR-derived gene editing technology. By refining the tools required for precise correction of disease-causing mutations, Prime Medicine aims to develop single-dose treatments that address underlying genetic drivers of disease. The company applies its proprietary engineering and delivery platforms to optimize on-target efficiency and minimize off-target effects, positioning itself at the forefront of next-generation gene editing therapeutics.

Prime Medicine’s research and development efforts span multiple therapeutic areas, including rare genetic disorders, immuno-oncology, and autoimmune diseases.